Virtual Meeting Activity Descriptions 2020...participants attended >80% of the full webinar. To receive credit for the activity, participants must listen to the webinar and complete

Meeting Information

CE Requirement For On Demand Online Evaluation In order to receive credit, participants must watch the video and get a 70% or better on the post test at the end of each CPE activity. Participants must also submit an evaluation for each CE activity completed. You will have until June 30, 2021 to complete the CEs. Once you have completed all of the activities that you are interested in completing you must click on the submit CE credits in order to have the CE uploaded to the CPE Monitor. Once you submit the CE credits you will no longer be able to access the trainings. CE Requirement For Live (Webinar)– Online Evaluation You must register for the gotowebinar and attendance will be taken with our GoToWebinar software to confirm that participants attended >80% of the full webinar. To receive credit for the activity, participants must listen to the webinar and complete the evaluation for the webinar in SurveyMonkey. WSPA staff will upload the CE for the live activities within 3‐4 weeks to the CPE Monitor. An email will be sent to participants once the CE has been uploaded. ACPE does not allow any CPE uploads after 60 days from the activity date. It will be the participants responsibility to verify that all CE activities attended are showing on their CPE Monitor. If there is a problem, please contact WSPA staff at 425‐228‐717 ext. 0. In order to process CE credits, participants must provide the correct NABP e‐Profile ID number and their birth month and day (MMDD format). The NABP e‐Profile ID number is a six to eight‐digit number, and it is NOT your license number, NPI number, or store NABP#. If you need to verify your number or have not yet registered for one, please visit www.MyCPEMonitor.net.

The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education

Technician or Pharmacist Accredited CE The CPE programs accredited for pharmacists will have a designation of “P” next to the ACPE number. CPE activities accredited for technicians will have a “T”. For example, “ACPE # 130‐000‐17‐045‐L04 P&T” is accredited for both pharmacists and technicians. How to understand CE subject classification ACPE # 130‐000‐20‐045‐L04 P&T; this ACPE number has L04 which means it’s a live event and general pharmacy, if it was H04 it would represent that it was a home study CE. A list of definitions is below: L01‐ Disease/Drug Therapy L02‐ HIV/AIDS L03‐ Law L04‐ General Pharmacy L05‐ Safety L06‐ Immunizations L07‐ Compounding L08‐ Pain Management/Opioid

Live Webinar Activity Description & Agenda These sessions will be recorded and made available as on demand CEs. Participants will have access to the Virtual Northwest Pharmacy Convention on demand CE sessions via their LecturePanda link until June 30, 2021.

Forum Wednesday, May 27, 2020

Independent Pharmacy Forum Wednesday, May 27 | 8:00 – 9:00 am PT | 9:00 am – 10:00 am MT Faculty: Bob Graul, R.Ph., MBA, Business Development Consultant, First Financial Bank, Chad Roberts, MBA, Founder, TouchPoint Studio and Simeon Roth, Pharm.D., Director of Operations,

Clinical Instructor UW School of Pharmacy, Owner, Invara Pharmacy Moderator: Michael Donohue, R.Ph., FACA, Pharmacist/Owner, Bob Johnson's Pharmacy 1 hr. | ACPE# 0130‐0000‐20‐149‐L04‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacists, Technicians, Student At the completion of this activity, the pharmacist and technician will be able to:

Discuss current trends in pharmacy practice

Describe specific issues and needs pertaining to practice This activity is designed to target the needs of pharmacists, technicians and interns working in an independent pharmacy setting. Bob Graul from First Financial Bank will be discussing trends in industry and financing strategy. Chad Roberts from TouchPoint Studio and Simon Roth from Invara Pharmacy will discuss use of technology to achieve the pharmacy’s goals.

Community Practice Forum Wednesday May 27 | 10:00 am – 11:00 am PT | 11:00 am – 12:00 pm MT Moderator: Tara Pfund, Pharm.D., Clinical Program Development, Kroger Health 1 hr. | ACPE# 0130‐0000‐20‐174‐L04‐P&T Activity Type: Knowledge |Conflict of Interest: None Target Audience: Pharmacists, Technicians, Student

At the completion of this activity, the pharmacist and technician will be able to:

Describe current trends in pharmacy practice

Discuss Community Pharmacy's Response to the COVID‐19 Pandemic

Define state and federal legislative/regulatory issues pertaining to pharmacy

This CE program is designed to target the needs of pharmacists, technicians and interns working in Community Practice pharmacy settings. We will discuss the current issues affecting pharmacy practice in general as well as how these issues relate to this practice setting. This will be an interactive session and participants will be encouraged to both contribute their thoughts and network during this interactive session.

Long Term Care Forum Wednesday May 27 | 11:00 am – 12:00 pm PT | 12:00 pm – 1:00 pm MT Moderator: Jenny Arnold, Pharm.D., BCPS, Director of Practice Development, WSPA 1 hr. | ACPE# 0130‐0000‐20‐150‐L04‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student

At the completion of this program, the pharmacist and technician will be able to:


Discuss specific issues and needs pertaining to your practice setting


This CE activity is designed to target the needs of pharmacists, technicians and interns working in Long Term Care Practice pharmacy settings. We will discuss the current issues affecting pharmacy practice in general throughout the Pacific Northwest as well as how these issues relate to this practice setting. This will be an interactive session and participants will be encouraged to contribute their thoughts in this activity.

Ambulatory Care Forum Wednesday May 27 | 12:00 pm – 1:00 pm PT | 1:00 pm – 2:00 pm MT Faculty: Britt Sparks, MHA, CPHQ, PCMH CCE, Quality Program Manager, Quality Improvement & Accreditation, Network Quality and Performance Improvement, Kaiser Permanente Moderator: Ashley Van Allen, Pharm. D., BCACP, Ambulatory Pharmacy Clinical Manager, MultiCare Health System 1 hr. | ACPE# 0130‐0000‐20‐151‐L04‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student





This CE activity is designed to target the needs of pharmacists, technicians and interns working in Ambulatory Care Practice pharmacy settings. We will discuss population health in the clinic setting and the current issues affecting pharmacy practice in general throughout the Pacific Northwest as well as how these issues relate to this practice setting. This will be an interactive session and participants will be encouraged to contribute their thoughts in this activity.

Technician Forum Wednesday May 27 | 1:30 pm – 2:30 pm PT | 2:30 pm – 3:30 pm MT Moderators: Darell Connor, MHA, CPhT, CSPT, Regional Pharmacy Operations Manager, American Oncology Network, LLC and Katie Hone, Pharmacy Technician, Pharmacy Operations Manager Seattle Cancer Care Alliance 1 hr. | ACPE# 0130‐0000‐20‐152‐L04‐P&T | Activity Type: Knowledge Disclosure: None | Target Audience: Pharmacist, Technician, Student





Discuss strategies to reinforce a more patient‐centric mission for our profession

This CE program is designed to target the needs of technicians and students working in various pharmacy settings. We will discuss the current issues affecting local pharmacy practice in general as well as how these issues relate to this practice setting. Participants will be encouraged to contribute their thoughts in this active session.

Health Systems Forum Wednesday May 27 | 3:00 pm – 4:00 pm PT 4:00 pm – 5:00 pm MT Moderators: Michael Li, Pharm.D., Pharmacist, Kaiser Permanente, Erica Diamantides, Pharm.D., MHA, BCPS, Specialty Pharmacy Manager, UW Medicine, Pharmacy Services and Elaine Huang, Pharm.D., MHA, Assistant

Director of Pharmacy Supply Chain, UW Medicine 1 hr. | ACPE# 0130‐0000‐20‐153‐L04‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacists, Technicians, Student



Discuss specific issues and needs pertaining to health system practices


This CE program is designed to target the needs of pharmacists, technicians and interns working in Health System pharmacy settings. We will be talking about COVID‐19 and Resiliency. Other current issues affecting local pharmacy practice in general as well as how these issues relate to this practice setting will be discussed. Participants should bring their experiences and questions to this interactive session.

Student Forum: Resilience During Unprecedented Times (No CE Offered and this will not be available for OnDemand) Wednesday May 27 | 4:30 pm – 6:00 pm PT | 5:30 pm – 7:00 pm MT Faculty: Kevin Anderson Pharm.D., MBA, MHA, Pharmacist, UW Medicine and Amy Ngai, Pharm.D., MBA, MHA, Pharmacist, Seattle Cancer Care Alliance

At the completion of this program, the student will be able to:

Define resilience

Discuss methods to build resilience

Integrate methods to sustain resilience

Explore situations where resilience is required

A practical approach to understanding the dimensions of resilience. Explore real life situations that will help identify and practice resiliency skills in an interactive virtual setting (active participation required). Participants will leave with resources geared towards inspiring a growth mindset.

Thursday, May 28, 2020

Washington Law Update Thursday May 28 | 9:30 am – 11:00 am PT | 10:30 am – 12:00 pm MT

Faculty: Lauren Lyles‐Stolz, Pharm.D., Executive Director, Pharmacy Quality Assurance Commission, Health System Quality Assurance, Washington State Department of Health, Teri Ferreira, R.Ph., Regional Director of Operations – NW, Consonus

Pharmacy and Tim Lynch, Pharm.D., MS, FABC, FASHP, Vice President, Clinical Support Services, Chief Pharmacy Officer, Multicare Health System 1.5 hrs. | ACPE# 0130‐0000‐20‐154‐L03‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student At the completion of this program, the pharmacist and technician will be able to:

Discuss changes to Commission staff and how to engage in stakeholdering

Describe the Pharmacy Commission Rule Re‐write goals, process, results and next steps

Identify new and updated areas of practice regulation including COVID‐19 Temporary Waivers and Emergency Rules

State how to put patient safety and pharmacy care first while adhering to pharmacy law

This activity will discuss application of new laws and regulations. Topics will include new state requirements for licensure, inspection, professional standards and more. The PQAC Rules re‐write will be discussed, as well as impacts to practice.

Current Issues in Pharmacy Practice: Washington Thursday May 28 | 11:00 am – 12:30 pm PT | 12:00 pm – 1:30 pm MT

Faculty: Jeff Rochon, Pharm.D., Chief Executive Officer, Washington State Pharmacy Association and Megan McIntyre, Pharm.D., Pharmacist, Virginia Mason Medical Center 1.5 hrs. | ACPE# 0130‐0000‐20‐155‐L03‐P&T | Activity Type: Knowledge Disclosure: None | Target Audience: Pharmacist, Technician, Student


Discuss state and federal legislative/regulatory issues pertaining to pharmacy practice in Washington State

Describe current positive and negative trends in pharmacy practice

Describe the priorities of the Washington State Pharmacy Association

This program is designed to educate members on the current events pertaining to the Washington State practice of pharmacy in the last year and near future. Members are encouraged to voice their opinions and hear those of others in this interactive session.

Current Issues in Pharmacy Practice: Idaho Thursday May 28 | 2:30 pm – 4:00 pm PT | 3:30 pm – 5:00 pm MT Faculty: Pam Eaton, Executive Director, Idaho State Pharmacy Association 1.5 hrs. | ACPE# 0130‐0000‐20‐156‐L03‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student


Discuss current pharmacy issues in Idaho and at the national level

List Idaho State Pharmacy Association’s activities over the past year

This activity is designed to educate members on the importance of the Idaho State Association and how it impacts everyday operations as well as the profession as a whole. Members will walk away from this meeting with an understanding of current issues facing pharmacy in Idaho and how they can become actively involved in shaping the practice of pharmacy on a state level.

2020 Idaho Law Update and Review Thursday May 28 | 4:00 pm – 5:30 pm PT | 5:00 pm – 6:30 pm MT

Faculty: Nicole Chopski, Pharm.D., BCGP, ANP, Executive Director, Idaho Board of Pharmacy 1.5 hrs. | ACPE# 0130‐0000‐20‐157‐L03‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student


Discuss the 2020 rule changes impacting the profession of pharmacy in Idaho

Describe the 2020 statutory changes impacting pharmacy practice in Idaho

Explain the effect Zero Based Regulation will have on 2021 rulemaking in Idaho

Restate current rules for key topics

Attendees will gain an understanding of current regulatory issues including recent statute and rules changes.

Friday, May 29, 2020

Current Issues in Pharmacy Practice: Montana Friday May 29 | 8:00 am – 9:30 am PT | 9:00 am – 10:30 am MT

Faculty: Stuart Doggett, Executive Director, Montana Pharmacy Association 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐158‐L03‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student


Discuss pharmacy legislation passed during 2019 Montana Legislative Session

Explain Montana Board of Pharmacy rules and other changes

List state and federal policies changes impacting pharmacist

Montana pharmacists are urged to attend the Montana member meeting for updates on state and federal issues.

Montana Law Update Friday May 29 | 9:30 am – 11:00 am PT | 10:30 am – 12:00 am MT

Faculty: Tony King, R.Ph., Director of Pharmacy Programs, Mountain Pacific Quality Health 1.5 hrs. | ACPE# 0130‐0000‐20‐159‐L03‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student

At the completion of this presentation, the pharmacist should be able to:

Identify who will be required to register to use the Montana Prescription Drug Registry

Determine which legislative measure allows for the Montana Prescription Drug Registry to integrate with EMRS, HIEs, and dispensing systems

Discuss the outcome of HB 231 in regard to a pharmacists’ ability to immunize patients

At the completion of this presentation, the technician should be able to:

Identify the current certified pharmacy technician member of the Montana Board of pharmacy

Discuss the pros/cons with adding additional levels to technician licensure

Discuss the pending rule change that would affect the pharmacist to technician ratio in Montana This session will be an open/interactive discussion of the current landscape of federal and state regulations including a recap of the 2019 Montana legislative session, current proposed rule changes and an update of the NABP national convention.

Keynote Presentation

The Future of Pharmacy Friday May 29 | 11:30 am – 1:00 pm PT | 12:30 am – 2:00 pm MT Faculty Scott Knoer, M.S., Pharm.D., FASHP, CEO EVP, American Pharmacists Association 1.5 hrs. | ACPE# 0130‐0000‐20‐160‐L04‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Students

At the completion of this program, the pharmacist will be able to:

Identify significant disruptive innovations that will impact healthcare

Describe the strategy for provider status at the national and state levels

Describe the importance of advocacy in professional advancement

At the completion of this program, the technician will be able to:

Identify significant disruptive innovations that will impact healthcare

Describe the importance of changing financial reimbursement models for pharmacy services

Describe the importance of technician certification

Dr. Knoer’s presentation will focus on identifying significant disruptive innovations that will impact healthcare, strategy for provider status, changing financial reimbursement models for pharmacy services, the importance of technician certification and more. Scott Knoer, MS, PharmD, FASHP is the 13th Executive Vice President and Chief Executive Officer of the American Pharmacists Association as of May 1, 2020. He was previously the Chief Pharmacy Officer at the Cleveland Clinic from 2011 to 2020 where he led an international pharmacy enterprise with a $1.4 billion dollar drug budget and 1,558 FTEs in 18 hospitals with facilities in Ohio, Florida, Nevada; Toronto, Ontario, Canada; London, England; and Abu Dhabi, UAE. Dr. Knoer received his BA in psychology from Creighton University in 1988 and his PharmD from the University of Nebraska in 1996. He completed a two‐year administrative residency with a concurrent MS degree in hospital pharmacy from the University of Kansas in 1998.

Dr. Knoer is frequently quoted as a healthcare expert on a broad array of topics in newspaper, radio and television outlets such as the Wall Street Journal, the Washington Post, the New York Times, STAT News, Modern Healthcare, NPR Radio, CNBC and many others. He has published editorials in Time Magazine, Newsweek, STAT First Opinion and the Hill.

Among many honors, Dr. Knoer was recognized for his advocacy related to egregious drug price increases by ASHP with their Board of Director’s Award of Excellence in 2017 and by the ASHP SPPM with their Advocacy Award in 2016. He also received the SPPM Distinguished Service Award in 2015 and was chosen for the John W. Webb Lecture Award for excellence in pharmacy management in 2019. Dr. Knoer received the Harold N. Godwin Legacy Leadership Award from the University of Kansas School of Pharmacy in 2016 and the Hugh F. Kabat Award from the Minnesota Society of Health‐System Pharmacists in 2009. He was awarded the Evlyn Gray Scott Award from the Cleveland Society of Health‐System Pharmacists in 2017.

Activity Description for On Demand CPE

Pharmacogenetic Feasibility Study in Retirement Communities Faculty: Jennifer Wilson Norton, BS Pharm., MBA, Associate Professor, University of Washington School of Pharmacy, Lena Chaitesipaseut, MBA, Pharm.D., Student Class of 2021 and Tamatha Mikes, Pharm.D., Student Class of 2021 .75 hr. CPE | ACPE# 0130‐0000‐20‐161‐H04‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student


Define lesson learned from a small feasibility study

Explain how pharmacogenetic testing/results could impact people across practice settings

State how to apply and integrate provider skills related to common pharmacogenetic results into multiple practice settings

The University of Washington School of Pharmacy in partnership with two retirement communities in Seattle performed a pharmacogenetic feasibility study on commonly prescribed medications in the geriatric practice. This work resulting in rich lesson learned for the research team, the residents and the staffs of Era Living. Please join us for this lively conversation.

Insomnia: Systematic Approach for Selection of Pharmacological Therapies Faculty: Quyen A. Nguyen, Pharm.D., Pharmacy Resident, Providence Medical Group 1 hr. CPE | ACPE# 0130‐0000‐20‐162‐H01‐P| Activity Type: Application | Disclosure: None Target Audience: Pharmacist, Student


Define insomnia and the sleep parameters for insomnia management

Discuss necessary strategies that should be implemented before consideration of pharmacological therapies

Differentiate pharmacologic agents indicated for insomnia by their risks and benefits

Apply concepts of insomnia management into a patient case

Insomnia is a very common health issue that many people experience. People often seek for medications to help with the issue, without realizing that there are many different non‐pharmacological interventions which can be utilized to manage insomnia. When pharmacological therapies are needed, patients and providers often encounter difficulty of selecting which therapy will be the most appropriate. Today, we will review how to systemically approach a patient with insomnia and select patient‐specific non‐pharmacological and pharmacological therapies.

The Skinny on Fad Diets Faculty: Steven Elrod, Pharm.D., BCACP, Faculty Pharmacist, Providence Chehalis Family Medicine 1 hr. CPE | ACPE# 0130‐0000‐20‐163‐H01‐P&T | Activity Type: Application | Disclosure: None Target Audience: Pharmacist, Technician, Student


Compare fad diets for benefits of weight loss and cardiovascular protection

Assess medications indicated for weight loss in comparison to fad diets

Select which diet and/or medication could be beneficial for patients

It seems like every other day we are hearing about a new diet that will work wonders with minimal amount of effort needed. Between the bevvy of commercials, advertisements, and pyramid schemes, it is becoming tougher and tougher to decide which information is believable or not. Today, we’ll review some of the fad diets and compare them to weight loss medications for short‐ and long‐term success.

Rounding Up or Down? Approach to Treating Latent Autoimmune Diabetes in Adults Faculty: Janelle Wortman, Pharm.D., PGY2 Ambulatory Care Resident, Providence St. Peter Family Medicine 1 hr. CPE | ACPE# 0130‐0000‐20‐164‐H01‐P| Activity Type: Application | Disclosure: None Target Audience: Pharmacist, Student


Describe LADA pathophysiology

Explain how to screen, test, and interpret lab results for LADA

Apply evidence‐based medicine to create appropriate LADA treatment plans Patients with diabetes truly come in all shapes and sizes, reflective of the multifaceted nature of the disease. Consider patients that have a type 2 diabetes diagnosis but don’t quite fit the traditional type 2 picture, or patients who have already been diagnosed with LADA or “type 1.5 diabetes.” Pharmacists and other healthcare providers should know when and how to test for LADA and, once a diagnosis is made, how it changes our treatment approach. In this session, we’ll learn what LADA is, what we know about it, and how you can apply it to your daily practice.

We’ve Come A‐Lung Way in Asthma Treatment Faculty: Lindsey M. Hutnick, Pharm.D., BCACP, Pharmacist, Virginia Garcia Memorial Health Center 1.0 hr. CPE | ACPE# 0130‐0000‐20‐165‐H01‐P| Activity Type: Application | Disclosure: None Target Audience: Pharmacist, Student


Modify clinical practice based on new guideline updates

Identify clinically inappropriate use of SABA in patients with asthma

Evaluate symptom control and future risk for asthma exacerbations

Design patient specific treatment plan to prevent asthma exacerbations Inhaled SABAs have been the standard first‐line treatment for mild asthma for 50 years…until now. The new 2019 Global initiative for Asthma (GINA) says its recommendations for treatment of mild asthma “may be considered the most fundamental change in asthma management in 30 years”. Today, we will review the major changes of the 2019 GINA report and the supporting data, focusing on changes for mild asthma. After reviewing, we will spend time working through cases to solidify the understanding of the new recommendations. You won’t want to miss this!

Practical Applications of the 2019 Beers Criteria Faculty: Jeffrey Clark Pharm.D., BCGP, Clinical Assistant Professor, Washington State University 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐166‐H04‐P| Activity Type: Knowledge Disclosure: Independent Grant for Learning and Change‐ Pfizer Target Audience: Pharmacist, Student


Describe the new updates contained within the 2019 Beers criteria®

Describe how to use the 2019 Beers Criteria® appropriately and how to avoid pitfalls when applying the criteria.

Recognize common scenarios when a change could be recommended based the 2019 Beers Criteria®

Checking In: Tools for Wellbeing, Burnout, and Compassions Fatigue Faculty: Christina R. Buchman, Pharm.D., BCACP, Clinical Assistant Professor, Washington State University and Damianne Brand‐Eubanks, Pharm.D., Clinical Assistant Professor, Washington State University 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐167‐H04‐P&T | Activity Type: Application Disclosure: None | Target Audience: Pharmacist, Student


Discuss provider wellbeing and recognize signs and symptoms of compassion fatigue and burnout

Explore assessment tools for evaluating current state of wellbeing of yourself, staff, and students

Formulate implementation strategies to improve wellbeing We will spend time discussing and evaluating pharmacist, technicians and student wellbeing as it relates to burnout and compassion fatigue. We will provide an overview of what wellbeing, burnout, and compassion fatigue entails and how standard pharmacy practice and work life balance impacts or wellbeing. Then we will go through several of the tools that are being used to assess wellbeing and burnout and have participants evaluate their own wellbeing. Participants will then work together to discuss and formulate strategies to improve wellbeing in their practice sites as well as to recognize the signs and symptoms of others that may be suffering from burnout and deceased wellbeing.

GendeRx: Providing Care for Trans and Gender Diverse Patients in the Pharmacy Faculty: Rachel Tsai, Pharm.D. Candidate, University of Washington School of Pharmacy, Sam Miller, Pharm.D. Candidate, University of Washington School of Pharmacy, Tara O’Connell, Pharm.D. Candidate, University of Washington School of Pharmacy, and Brian Peznowski, Pharm.D. Candidate, University of Washington School of Pharmacy 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐168‐H04‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student At the completion of this program, the pharmacist will be able to:

Define appropriate terminology to reflect the language patients use to identify themselves

Identify factors contributing to the health disparities experienced by gender diverse patients

Discuss pharmacotherapeutics for feminizing and masculinizing therapy

Recognize opportunities to make your practice setting more inclusive Locate available guidelines and resources to provide gender affirming care At the completion of this program, the technician will be able to:

Define appropriate terminology to reflect the language patients use to identify themselves

Identify factors contributing to the health disparities experienced by gender diverse patients

Recognize opportunities to make your practice setting more inclusive An overview of gender diversity and transgender healthcare in pharmacy presented by QueeRx, the student run LGBTQ+ organization from the University of Washington’s School of Pharmacy.

The Role of a Pharmacist in a Hematology/Oncology Clinic: Implementation, Supportive Care, and Oral Chemotherapy Agents Faculty: Matthew Chui, Pharm.D., Clinical Pharmacist, University of Miami 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐169‐H01‐P&T | Activity Type: Knowledge | Disclosure: Advisory Committees or Review Panels: Astra Zeneca Target Audience: Pharmacist, Technician, Student


Explain the potential role of a clinical pharmacist in a hematology/oncology clinic

Evaluate appropriate anti‐infective agents for patients with hematologic malignancies on chemotherapy

Discuss unique side‐effects for oral chemotherapy agents used in patients with hematologic malignancies


State the mechanism of action of common oral chemotherapy agents used in heme/onc settings

Explain common side effects of oral chemotherapy agents

List anti‐infective agents used in hematologic malignancies

Psychopharmacotherapy in Youth Faculty: Ian McGrane, Pharm.D., BCPS, BCPP, Assistant Professor, University of Montana 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐170‐H01‐P&T | Activity Type: Knowledge | Disclosure: Royalty, Hogrefe Publishing Group; editor for Clinical Handbook of Psychotropic Drugs for Children and Adolescents: 4th Edition (2019) Target Audience: Pharmacist, Technician, Student


Identify FDA approved drugs for major depressive disorder, generalized anxiety disorder, bipolar disorder, schizophrenia, and attention‐deficit/hyperactivity disorder

Describe the 2004 FDA boxed warning for antidepressant drugs

Recommend monitoring parameters for patients taking antidepressants, anxiolytics, mood stabilizers, antipsychotics, and ADHD medications


Identify FDA approved drugs for major depressive disorder, generalized anxiety disorder, bipolar disorder, schizophrenia, and attention‐deficit/hyperactivity disorder

Describe the 2004 FDA boxed warning for antidepressant drugs

Identify monitoring parameters for patients taking antidepressants, anxiolytics, mood stabilizers, antipsychotics, and ADHD medications

Questions often arise regarding the appropriate use and monitoring of psychiatric drugs in children and adolescents. This programing will review some of the most common classes of psychopharmacotherapy including antidepressants, anxiolytics, mood stabilizers, antipsychotics, and medications for attention‐deficit/hyperactivity disorder. Content‐based questions will be used to meet the proposed learning objectives.

E‐Cigarette or Vaping Product Use‐Associated Lung Injury (EVALI) Faculty: Sorosh Kherghehpoush, Pharm.D., Research Fellow, Washington State University 1 hr. CPE | ACPE# 0130‐0000‐20‐171‐H01‐P&T | Activity Type: Knowledge | Disclosure: None Target Audience: Pharmacist, Technician, Student


Define EVALI and discuss potential causes

Describe the role of Vitamin E Acetate in the pathology of EVALI

Recall the CDC recommendations on vaping

Discuss current literature on the use of electronic‐nicotine delivery systems (ENDS) for smoking cessation in adults

In the summer of 2019, the first cases of E‐Cigarette or Vaping product use‐Associated Lung Injury (EVALI) were identified since the introduction of Vaping to the US market more than 10 years ago. The FDA has raised the federal minimum age requirement to purchase tobacco from 18 to 21 and there have been proposed state and federal bans on flavored nicotine products. This presentation will provide up to date information on EVALI and current CDC recommendations, vaping and tobacco‐use trends among teens and adults, and a review of current literature outlining the use of Electronic Nicotine Delivery Systems (ENDS) for smoking cessation.

Diabetes Update: New Treatment Recommendations and Approaches for 2020 Faculty: Joshua J. Neumiller, Pharm.D., CDCES, Associate Professor, Washington State University CPPS 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐172‐H01‐P&T | Activity Type: Application | Disclosure: None Target Audience: Pharmacist, Technician, Student


Discuss recommendations from the 2020 ADA Standards of Medical Care in Diabetes for use of glucose‐lowering medications in patients with type 2 diabetes;

Describe patient‐ and medication‐specific considerations to selection of glucose‐lowering medications for patients with type 2 diabetes; and

Apply recommendations from the 2020 ADA Standards of Medical Care in Diabetes to a patient case.


Describe recommendations from the 2020 ADA Standards of Medical Care in Diabetes for use of glucose‐lowering medications in patients with type 2 diabetes;

Appreciate patient‐ and medication‐specific considerations to selection of glucose‐lowering medications for patients with type 2 diabetes; and

Recognize potential benefits of glucose‐lowering agents in patients with type 2 diabetes.

Pharmacy professionals frequently encounter people with type 2 diabetes (T2D). Not only does the number of medications approved for the treatment of T2D continue to expand at a rapid rate, but our understanding of how glucose‐lowering medications impact cardiovascular and renal risk also continues to evolve. This presentation will use a case‐based approach to review recent updates to the American Diabetes Association (ADA) Standards of Medical Care in Diabetes while also highlighting recently approved medications and new indications recently granted for existing glucose‐lowering drugs.

Intellectuals Solve Problems, Geniuses Prevent Them: How to Be a Genius and Prevent the Top Causes of Disease in America Faculty: Skye McKennon, Pharm.D., BCPS, ACSM‐CEI, Lead Author, Adjunct Faculty, Kendall Hunt Publishing, Washington State University 1.5 hrs. CPE | ACPE# 0130‐0000‐20‐173‐H01‐P&T | Activity Type: Application | Disclosure: None Target Audience: Pharmacist, Technician, Student

At the completion of this program, the pharmacist and will be able to:

List the top 5 causes of death in the United States.

Access billing code for common preventive health services.

Paraphrase the ACC/AHA 2019 guidelines for prevention of cardiovascular disease.

State the role of aspirin therapy in primary cardiovascular disease prevention.

Recommend preventive therapy for the primary prevention of cardiovascular disease (particularly the use of statins, ezetimibe, and PCSK9 inhibitors).

Distinguish evidence‐based chemoprophylaxis of cancer.

Apply lifestyle recommendations for activities that convincingly increase and decrease the risk of specific cancers.

Create an evidence‐based preventive health regimen for a patient trying to prevent heart disease and cancer.

At the completion of this program, the technician and will be able to:

List the top 5 causes of death in the United States.

Access billing code for common preventive health services.

Paraphrase the ACC/AHA 2019 guidelines for prevention of cardiovascular disease.

State the role of aspirin therapy in primary cardiovascular disease prevention.

Describe preventive therapy for the primary prevention of cardiovascular disease (particularly the use of statins, ezetimibe, and PCSK9 inhibitors).

Distinguish evidence‐based chemoprophylaxis of cancer.

List lifestyle recommendations for activities that convincingly increase and decrease the risk of specific cancers.

Judge an evidence‐based preventive health regimen for a patient trying to prevent heart disease and cancer.

Albert Einstein, dubbed one of the greatest scientists of all time, said, “Intellectuals solve problems, geniuses prevent them.” Take a page from Einstein and attend this exciting CE program that will empower you with evidence‐based knowledge on preventing two common and debilitating conditions – cardiovascular disease and cancer. Chemoprophylaxis and evidence‐based lifestyle recommendations will be covered. Be prepared to leave with simple and actionable interventions to make you and your patients healthier.

Documents

Virtual Meeting Activity Descriptions 2020...participants attended >80% of the full webinar. To receive credit for the activity, participants must listen to the webinar and complete